首页 > 市场调查报告书 > 製药

药物开发

市场调查报告书

商品编码

1419130

药物发现服务市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围：按工艺、类型、分子类型、治疗领域、最终用户和地理位置

Drug Discovery Services Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Process, Type, Molecule Type, Therapeutic Area, End User, and Geography

出版日期: 2023年11月17日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格

简介目录

药物发现服务市场预计将从2022年的195.39亿美元成长到2030年的567.83亿美元；预计2022年至2030年CAGR为14.3%。

药物发现是识别和开发新药物来治疗疾病和改善人类健康的过程。它涉及潜在候选药物的识别、在实验室和动物模型中的合成和测试，以及最终在人体临床试验中的评估。药物发现服务透过提供一系列专业知识和资源来支持药物发现过程。这可以包括药物化学、计算建模、高通量筛选和临床前测试服务。这些服务通常由合约研究组织 (CRO) 或学术研究机构提供。製药公司和生物技术公司利用它们来加速药物发现过程并更有效地将新药物推向市场。

慢性病盛行率的不断上升推动了药物发现服务市场的成长。

癌症、糖尿病、心血管疾病和呼吸系统疾病等慢性疾病的盛行率不断上升，对医疗保健产业的发现服务产生了巨大的需求。根据美国疾病管制与预防中心(CDC)2022年公布的资料，美国将有约3,730万名糖尿病患者，占美国总人口的11.3%。随着慢性和复杂疾病的盛行率持续上升，对能够解决未满足的医疗需求并改善患者治疗效果的创新治疗方法的需求不断增长。此外，由于预期寿命的延长，60多岁及以上的人越来越多。根据联合国2020年世界人口老化资料库，全球老年人口数量预计将从2020年的7.27亿增加到2050年的15亿。老年人口更容易患慢性病，这增加了对慢性病的需求管理部门。久坐行为的增加将大大影响药物发现服务市场。药物发现服务在新药和医疗技术的开发中发挥重要作用。他们帮助製药公司和研究机构识别和验证潜在的药物标靶，进行临床前研究，并优化临床试验的候选药物。这对于将新的有效治疗方法推向市场以解决日益严重的慢性病负担至关重要。

此外，对个人化医疗和精准医疗的日益关注进一步刺激了对发现服务的需求。公司越来越多地寻求根据个别患者的基因组成和其他因素开发量身定制的治疗方法。这种个人化的医学方法需要广泛的研究和发现服务，以确定适合每个患者独特需求的最有效的治疗方法。因此，随着医疗保健行业致力于解决慢性病负担不断增加并改善患者治疗效果，发现服务市场预计将继续增长。由于对创新治疗和个人化医疗的需求继续推动医疗保健领域的研究和开发，对这些服务的需求可能会保持强劲。

药物发现服务市场根据流程、类型、分子类型、治疗领域和最终用户进行划分。根据流程，药物发现服务市场分为标靶选择和验证、先导化合物识别等。按类型划分，药物发现服务市场分为生物服务、药物化学药物代谢和药物动力学。从分子类型来看，药物发现服务市场分为生物製剂和小分子。根据治疗领域，药物发现服务市场分为心血管疾病、肿瘤、神经学、糖尿病、呼吸系统疾病等。此外，最终用户部分分为製药和生技公司、学术机构和其他。

根据地理位置，药物发现服务市场分为北美、欧洲、亚太地区、中东和非洲以及南美洲和中美洲。北美是药物发现服务市场成长的最重要贡献者。该地区的成长归因于多种因素，包括药物开发公司投资的增加、美国政府的大量资助、大型药物开发公司的强大影响力、发达的医疗基础设施以及不断增长的医疗保健基础设施。在慢性疾病中。

根据美国癌症协会的《2022 年癌症事实与数据》，预计到 2022 年底，美国将新增约 1,918,030 例癌症病例，并有 609,360 例癌症相关死亡。鑑于该地区癌症发病率较高，预计癌症药物的寻找将加速市场扩张。此外，预计该地区的药物发现市场将受到美国药物发现技术的突破激增。例如，CytoReason 与辉瑞于 2022 年 9 月签署了一项多年合作协议，以便辉瑞可以利用 CytoReason 的人工智慧技术进行药物开发。美国主要市场参与者在药物发现中采用人工智慧技术预计将推动该领域正在研究的市场的扩张...

疾病管制与预防中心 (CDC) 以及食品药物管理局 (FDA) 是在准备药物发现服务市场报告时提到的几个关键的主要和次要来源。

欧洲
- 德国
- 法国
- 义大利
- 西班牙
- 英国
- 欧洲其他地区
亚太
- 澳洲
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地区

第 13 章：Covid-19 前后的影响

第 14 章：产业格局

併购
协议、合作、合资企业
新产品发布
扩张和其他策略发展

第15章：竞争格局

关键参与者的热图分析
公司定位与专注

第 16 章：药物发现服务市场 - 主要公司概况

Abbott Laboratories

注意 - 将为以下公司列表提供类似信息

安捷伦科技
无所不在
奥尔巴尼分子研究公司
阿斯特捷利康公司
奥里金
拜耳公司
查尔斯河国际实验室
康桥公司
科文斯

第 17 章：附录

词彙表
关于 Insight Partners
市场情报云

简介目录

Product Code: TIPRE00003410

The drug discovery services market is expected to grow from US$ 19.539 billion in 2022 to US$ 56.783 billion by 2030; it is anticipated to record a CAGR of 14.3% from 2022 to 2030.

Drug discovery is the process of identifying and developing new medications to treat diseases and improve human health. It involves the identification of potential drug candidates, their synthesis and testing in laboratory and animal models, and ultimately, their evaluation in clinical trials in humans. Drug discovery services work by providing a range of specialized expertise and resources to support the drug discovery process. This can include medicinal chemistry, computational modeling, high-throughput screening, and preclinical testing services. These services are often provided by contract research organizations (CROs) or academic research institutions. Pharmaceutical companies and biotechnology firms use them to accelerate the drug discovery process and bring new medications to market more efficiently.

The increasing prevalence of chronic diseases drives the growth of the drug discovery services market.

The increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases is creating a significant demand for discovery services in the healthcare industry. According to data published by the CDC in 2022, in the US, there will be around 37.3 million people with diabetes, which is 11.3% of the US population. As the prevalence of chronic and complex diseases continues to rise, there is a growing need for innovative treatments that can address unmet medical needs and improve patient outcomes. Furthermore, an increasing number of people are in their 60s and beyond due to increases in life expectancy. The number of older individuals worldwide is expected to increase from 727 million in 2020 to 1.5 billion by 2050, according to the United Nations Database on World Population Ageing 2020. The older population is more vulnerable to chronic illnesses, which increases demand for the chronic disease management sector. The rise in sedentary behavior would greatly impact the market for drug discovery services. Drug discovery services play an important role in the development of new drugs and medical technologies. They help pharmaceutical companies and research institutions identify and validate potential drug targets, conduct preclinical studies, and optimize drug candidates for clinical trials. This is essential for bringing new and effective treatments to market addressing the growing burden of chronic diseases.

In addition, the growing focus on personalized medicine and precision medicine has further fueled the demand for discovery services. Companies are increasingly seeking to develop tailored treatments for individual patients based on their genetic makeup and other factors. This personalized approach to medicine requires extensive research and discovery services to identify the most effective treatments for each patient's unique needs. Thus, the discovery services market is expected to continue to grow as the healthcare industry works to address the rising burden of chronic diseases and improve patient outcomes. The demand for these services is likely to remain strong as the need for innovative treatments and personalized medicine continues to drive research and development in the healthcare sector.

The drug discovery services market is divided on the basis of process, type, molecule type, therapeutic area, and end user. Based on the process, the drug discovery services market is segmented into target selection and validation, hit to lead identification, and others - assay development and screening, etc. By type, the drug discovery services market is segmented into biology services, medicinal chemistry drug metabolism, and pharmacokinetics. In terms of molecule type, the drug discovery services market is classified as biologics and small molecules. On the basis of therapeutic areas, the drug discovery services market is differentiated into cardiovascular diseases, oncology, neurology, diabetes, respiratory diseases, and others. Furthermore, the end-user segment is classified into Pharmaceutical and Biotechnology Companies, Academic Institutes, and Others.

Based on geography, the drug discovery services market is divided into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. North America is the most significant contributor to the growth of the drug discovery services market. This region's growth has been attributed to a number of factors, including an increase in the investments made by drug development companies, large grants from the US government, a strong presence of major drug development companies, a well-developed healthcare infrastructure, and an increase in chronic diseases.

As per the American Cancer Society's "Cancer Facts & Figures 2022," it is projected that by the conclusion of 2022, there will be around 1,918,030 new cancer cases and 609,360 cancer-related deaths in the United States. Given the high rate of cancer in this area, it is expected that the search for cancer drugs will accelerate market expansion. Additionally, the drug discovery market in this region is anticipated to be driven by the surge in technical breakthroughs in drug discovery in the United States. For example, CytoReason and Pfizer signed a multi-year cooperation in September 2022 so that Pfizer could use CytoReason's artificial intelligence technology for medication development. The adoption of AI technology in drug discovery by major US market players is anticipated to propel the expansion of the market under study in this area...

Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA), are a few key primary and secondary sources referred to while preparing the report on the drug discovery services market.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Drug Discovery Services Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Drug Discovery Services Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Drug Discovery Services Market - Global Market Analysis

6.1 Drug Discovery Services - Global Market Overview
6.2 Drug Discovery Services - Global Market and Forecast to 2030

7. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Process, 2020-2030

7.1 Overview
7.2 Target Selection and Validation
7.3 Hit To Lead Identification
7.4 Others

8. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Type, 2020-2030

8.1 Overview
8.2 Biology Services
8.3 Medicinal Chemistry
8.4 Drug Metabolism and Pharmacokinetics

9. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Molecule Type, 2020-2030

9.1 Overview
9.2 Biologics
9.3 Small Molecules

10. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Therapeutic Area, 2020-2030

10.1 Overview
10.2 Cardiovascular Diseases
10.3 Oncology
10.4 Neurology
10.5 Diabetes
10.6 Respiratory Diseases
10.7 Others

11. Drug Discovery Services Market - Revenue Analysis (USD Million) - By End User, 2020-2030

11.1 Overview
11.2 Pharmaceutical and Biotechnology Companies
11.3 Academic Institutes
11.4 Others

12. Drug Discovery Services Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

12.1 North America
- 12.1.1 North America Drug Discovery Services Market Overview
- 12.1.2 North America Drug Discovery Services Market Revenue and Forecasts to 2030
- 12.1.3 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Process
- 12.1.4 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Type
- 12.1.5 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Molecule Type
- 12.1.6 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Therapeutic Area
- 12.1.7 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By End User
- 12.1.8 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Countries
  - 12.1.8.1 United States Drug Discovery Services Market
    - 12.1.8.1.1 United States Drug Discovery Services Market, by Process
    - 12.1.8.1.2 United States Drug Discovery Services Market, by Type
    - 12.1.8.1.3 United States Drug Discovery Services Market, by Molecule Type
    - 12.1.8.1.4 United States Drug Discovery Services Market, by Therapeutic Area
    - 12.1.8.1.5 United States Drug Discovery Services Market, by End User
  - 12.1.8.2 Canada Drug Discovery Services Market
    - 12.1.8.2.1 Canada Drug Discovery Services Market, by Process
    - 12.1.8.2.2 Canada Drug Discovery Services Market, by Type
    - 12.1.8.2.3 Canada Drug Discovery Services Market, by Molecule Type
    - 12.1.8.2.4 Canada Drug Discovery Services Market, by Therapeutic Area
    - 12.1.8.2.5 Canada Drug Discovery Services Market, by End User
  - 12.1.8.3 Mexico Drug Discovery Services Market
    - 12.1.8.3.1 Mexico Drug Discovery Services Market, by Process
    - 12.1.8.3.2 Mexico Drug Discovery Services Market, by Type
    - 12.1.8.3.3 Mexico Drug Discovery Services Market, by Molecule Type
    - 12.1.8.3.4 Mexico Drug Discovery Services Market, by Therapeutic Area
    - 12.1.8.3.5 Mexico Drug Discovery Services Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

12.2 Europe
- 12.2.1 Germany
- 12.2.2 France
- 12.2.3 Italy
- 12.2.4 Spain
- 12.2.5 United Kingdom
- 12.2.6 Rest of Europe
12.3 Asia-Pacific
- 12.3.1 Australia
- 12.3.2 China
- 12.3.3 India
- 12.3.4 Japan
- 12.3.5 South Korea
- 12.3.6 Rest of Asia-Pacific
12.4 Middle East and Africa
- 12.4.1 South Africa
- 12.4.2 Saudi Arabia
- 12.4.3 U.A.E
- 12.4.4 Rest of Middle East and Africa
12.5 South and Central America
- 12.5.1 Brazil
- 12.5.2 Argentina
- 12.5.3 Rest of South and Central America

13. Pre and Post Covid-19 Impact

14. Industry Landscape

14.1 Mergers and Acquisitions
14.2 Agreements, Collaborations, Joint Ventures
14.3 New Product Launches
14.4 Expansions and Other Strategic Developments

15. Competitive Landscape

15.1 Heat Map Analysis by Key Players
15.2 Company Positioning and Concentration

16. Drug Discovery Services Market - Key Company Profiles

16.1 Abbott Laboratories
- 16.1.1 Key Facts
- 16.1.2 Business Description
- 16.1.3 Products and Services
- 16.1.4 Financial Overview
- 16.1.5 SWOT Analysis
- 16.1.6 Key Developments

Note - Similar information would be provided for below list of companies